Preserved systolic and diastolic cardiac function is seen in TREK-1-KO animals in response to pathological pressure overload stress, which may cause enhanced concentric hypertrophy and alterations in fetal gene expression.
Stroke work increased by 39%, and cardiac output was retained in TREK-1-KO mice after TAC, which aligns with noninvasive echocardiographic measurements of enhanced heart function. Not only did TREK-1-KO mice suggest improved cardiac contractility and exhibit apparently maintained diastolic function after TAC, as indicated by active relaxation and a 32% decrease in the minimum rate of LV pressure change (dP/min), but cardiac compliance was also measured by a preserved end-diastolic pressure-volume relationship (EDPVR).
Researchers investigated the role of TREK-1 in the heart’s reaction to chronic pressure overload using transverse aortic constriction (TAC), as this gene is upregulated in normal hearts and cardiac fibroblasts when pressure overload occurs, and biomechanical stress activates it. Global TREK-1-KO mice exhibited more concentric hypertrophy in response to TAC, but their heart function appeared to be unaffected compared to wild-type mice. Global TREK-1-KO mice appeared to have displayed no decline in cardiac function up to a year after TAC. Despite inducing fetal genes, decreasing expression of calcium-handling genes, activating calcineurin, and increasing Ca2 /calmodulin kinase II (CaMKII) activity as measured by phospholamban phosphorylation, cardiac function was preserved in global TREK-1-KO hearts.
“The fact that TREK-1-KO mice still have regular hearts even though they have all the hereditary and molecular features for heart failure indicates two things: first, that the pathways that control heart health can be distinguished from those that cause harmful remodeling of the heart, and second, that fibroblasts play a key part in the organism’s reaction to pressure surplus since TREK-1 is particularly deleted from fibroblasts and reforms normal heart function.”
SS-31 Peptide and Heart Hypertrophy
Cardiomyopathy involves many cellular pathways, one of which is phosphor-ERK1/2, and another is calcineurin-NFAT (nuclear factor of activated T-cells). When researchers investigated these in the hearts of aged mice, they did not detect changes in total or phosphorylated ERK1/2 levels. Atrial and brain natriuretic peptides (ANP/BNP), modulatory calcineurin interactin protein-1 (MCIP-1), and downstream cofactors like GATA4 all seemed activated with age within the calcineurin-NFAT pathway.
Calcineurin causes cell death by lowering membrane potential and mitochondrial stability. Apoptosis by mitochondrial instability is caused by the dephosphorylation of Bad and the enhancement of Bad heterodimerization with Bcl-XL, both of which are reportedly brought about by Ca2+-mobilizing agents. Mitochondria comprise about 30% of the whole intracellular volume within a mammalian cardiomyocyte. The mitochondrion is a double-membraned organelle that uses electron transport to produce ATP via oxidative phosphorylation. The last step in ATP synthesis is the action of mitochondrial Ht-ATPase, which transports protons into the mitochondrial matrix. It is common for injury stimuli to reduce membrane potential and oxygen consumption, both of which disrupt mitochondrial function. Silibinin was suggested to reverse the dissipation of membrane potential in the mitochondrial test to safeguard mitochondrial function.
SS-31 Peptide and Mitochondrial Membranes
Islet mitochondrial membrane potential is hypothesized to be maintained by the SS-31 peptide, which is believed to enter islet cells and co-localize with mitochondria. The results imply that the new antioxidant peptide SS-31 may potentially protect the mitochondrial membrane potential of isolated islets, possibly mitigate cell death, maximize islet production, and enhance the efficacy of islet grafts in cases of diabetes. A novel class of compounds for improving islet isolation and transplanting might include antioxidants that target mitochondria. Also, the mitochondrial membrane potential (MMP, ฮจm) was theorized to be marginally raised by intracellular SS-31-modified PLGA NPs before resuming.
SS-31 Peptide and Endoplasmic Reticulum Stress
“Considering that ER stress is frequently associated with an increase in cytosolic calcium content, the significant reduction of calcium content in the SS-31 T2D group compared to healthy research models may suggest a reduction of ER stress in these subjects. On the other hand, SS-20 did not affect calcium content under any circumstance.” Studies suggest that SS-31 may potentially mitigate both neuroinflammation and the oxidative stress that precedes it. Research indicates that an upstream regulator of neuroinflammation, SS-31, might promote SIRT1 to decrease HMGB1.
A 57% reduction in HMGB1 acetylation was speculated after incubation with SIRT1 on immunoprecipitated acetylated HMGB1. According to proteomic research, SIRT1 deacetylates HMGB1 on four lysine residues in the nuclear localization signal and proinflammatory domains (55, 88, 90, and 177). Increased HMGB1 acetylation and translocation were speculated after genetic ablation or pharmacological suppression of SIRT1 in endothelial cells. Deletion of SIRT1 in living organisms exacerbated kidney injury by decreasing nuclear HMGB1 and increasing its acetylation and release into the blood under baseline and ischemia circumstances. Conversely, after exposure to resveratrol, HMGB1 acetylation, nuclear retention, systemic release, and tubular damage seemed reduced. Then, a vicious loop begins in which inflammation-induced SIRT1 suppression prevents HMGB1 deacetylation, promoting its translocation from the nucleus to the cytoplasm and its release into the bloodstream, thereby perpetuating inflammation.
Cancer research suggests that inflammation may inhibit SIRT1 transcription via p53 and hypermethylation. In addition, it is speculated that SIRT1 mRNA may be destabilized, and its quantity may be reduced when the SIRT1 antigen R mRNA complex dissociates due to oxidative stress. Finally, the results purport a self-perpetuating loop whereby SIRT1 may be suppressed by inflammation, which in turn might prevent HMGB1 from being deacetylated and allow it to be transported from the nucleus to the cytoplasm and released into the bloodstream, thereby perpetuating the inflammation.
SS-31 Peptide and Type 2 Diabetes
In type 2 diabetes, the mitochondrial antioxidant SS-31 has been theorized to improve inflammation, oxidative stress, and interactions between leukocytes and endothelium by increasing SIRT1 levels.
Investigations purport that by blocking Fis1 expression in lipopolysaccharide-stimulated microglia, SS-31 might decrease inflammation and oxidative stress.
SS-31 Peptide and Friedreich Ataxia
The SS-31 peptide has been reported to mitigate the negative neurological consequences of brief sleep deprivation in aged rats.
SS-31 Peptide, Memory and Neuroplasticity.
“Suggesting a significant role for mitochondrial function in synaptic plasticity, presentation with SS-31 substantially reduced the reduction in plasticity regulator protein expression caused by sleep deprivation.”
Researchers examined the expression levels of three recognized regulators of synaptic plasticity to delve further into the cellular mechanism by which SS-31 may mitigate the learning deficit caused by sleep deprivation in aged mice. A glutamate receptor known as N-methyl-D-aspartate (NMDA) receptor is critical for controlling hippocampal synaptic plasticity and, by extension, function. Other key regulators of synaptic plasticity involved in learning and memory include:
– CREB (cAMP-response element binding).
– A transcription factor that lies downstream of the cAMP/PKA signaling pathway.
– BDNF (brain-derived neurotrophic factor).
The negative effects of short-term sleep deprivation on synaptic plasticity-related regulation may be due to high sensitivity to ROS-mediated inflammation in the brain, as suggested by significantly lower levels of NMDA receptor, p-CREB, and BDNF in SD mice compared to non-SD mice.
Findings imply that when given to mice, SS-31 may ameliorate lipopolysaccharide-induced mitochondrial dysfunction, synaptic dysfunction, and memory impairment.
Behavioral tests suggested that elamipretide exposure may have greatly improved LPS-induced memory and learning deficits. In particular, elamipretide appeared to have helped regulate brain-derived neurotrophic factor (BDNF) signaling, which may have increased synaptic structural complexity and reversed important synaptic-signaling proteins. It has also been hypothesized to protect against mitochondrial dysfunction and oxidative stress.
References
[i] Li, Ning, et al. โMiR-133: A Suppressor of Cardiac Remodeling?โ Frontiers in Pharmacology, vol. 9, 17 Aug. 2018, 10.3389/fphar.2018.00903.
[ii] Liang, Qiangrong, et al. โC-Jun N-Terminal Kinases (JNK) Antagonize Cardiac Growth through Cross-Talk with Calcineurin-NFAT Signaling.โ The EMBO Journal, vol. 22, no. 19, 1 Oct. 2003, pp. 5079โ5089, https://pubmed.ncbi.nlm.nih.gov/14517246/, 10.1093/emboj/cdg474.
[iii] Abraham, Dennis M., et al. โThe Two-Pore Domain Potassium Channel TREK-1 Mediates Cardiac Fibrosis and Diastolic Dysfunction.โ The Journal of Clinical Investigation, vol. 128, no. 11, 1 Nov. 2018, pp. 4843โ4855, https://www.jci.org/articles/view/95945, 10.1172/JCI95945.
[iv] Lee, Fan-Yen, et al. โCombined Therapy with SS31 and Mitochondria Mitigates Myocardial Ischemia-Reperfusion Injury in Rats.โ International Journal of Molecular Sciences, vol. 19, no. 9, 15 Sept. 2018, p. 2782, https://mdpi.com/1422-0067/19/9/2782/pdf, 10.3390/ijms19092782.
[v] Luo, Guiping, et al. โSirt1 Promotes Autophagy and Inhibits Apoptosis to Protect Cardiomyocytes from Hypoxic Stress.โ International Journal of Molecular Medicine, 6 Mar. 2019, 10.3892/ijmm.2019.4125.
[vi] Machiraju, Pranav, et al. โSS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From Patients With DCMA, a Mitochondrial Cardiomyopathy.โ Frontiers in Cardiovascular Medicine, vol. 6, 15 Nov. 2019, 10.3389/fcvm.2019.00167.
[vii] Karaa, Amel, et al. โRandomized Dose-Escalation Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy.โ Neurology, vol. 90, no. 14, 3 Apr. 2018, pp. e1212โe1221, pubmed.ncbi.nlm.nih.gov/29500292/, 10.1212/WNL.0000000000005255.
[viii] Liu, Yue, et al. โSS31 Ameliorates Sepsis-Induced Heart Injury by Inhibiting Oxidative Stress and Inflammation.โ Inflammation, vol. 42, no. 6, 7 Sept. 2019, pp. 2170โ2180, 10.1007/s10753-019-01081-3.
[ix] Szeto, Hazel H. โFirst-in-Class Cardiolipin-Protective Compound as a Therapeutic Agent to Restore Mitochondrial Bioenergetics.โ British Journal of Pharmacology, vol. 171, no. 8, 1 Apr. 2014, pp. 2029โ2050, https://ncbi.nlm.nih.gov/pmc/articles/PMC3976620/, 10.1111/bph.12461.
[x] Siegel, Michael P., et al. โMitochondrial-Targeted Peptide Rapidly Improves Mitochondrial Energetics and Skeletal Muscle Performance in Aged Mice.โ Aging Cell, vol. 12, no. 5, 11 June 2013, pp. 763โ771, 10.1111/acel.12102.
[xi] Supinski, Gerald S., et al. โSS31, a Mitochondrially Targeted Antioxidant, Prevents Sepsis-Induced Reductions in Diaphragm Strength and Endurance.โ Journal of Applied Physiology, vol. 128, no. 3, 1 Mar. 2020, pp. 463โ472, 10.1152/japplphysiol.00240.2019.